# Antimicrobial Resistance and ESBL-Associated Predictors Among Uropathogens: A 2019–2024 Isolate-Level Study

**Authors:** Raul-Lucian Ene, Roxana Popescu, Aurica Elisabeta Cobec, Daniela Puscasiu, Ileana-Adriana Ene, Daliborca Cristina Vlad, Ionut Marcel Cobec, Peter Seropian

PMC · DOI: 10.3390/antibiotics15030323 · Antibiotics · 2026-03-23

## TL;DR

This study analyzed antimicrobial resistance in uropathogens from 2019 to 2024, finding that ESBL production is a strong predictor of resistance.

## Contribution

The study identifies ESBL production as the most consistent and powerful predictor of antimicrobial resistance across multiple drugs in urinary tract infections.

## Key findings

- 17.3% of Gram-negative isolates were ESBL-positive.
- ESBL production was the strongest predictor of resistance to ciprofloxacin, amoxicillin/clavulanic acid, trimethoprim/sulfamethoxazole, and cefotaxime.
- Fosfomycin and nitrofurantoin showed high activity against Escherichia coli.

## Abstract

Background/Objectives: Urinary tract infections (UTIs) are among the most common bacterial infections and represent a major source of antimicrobial use. Increasing antimicrobial resistance among uropathogens, particularly the emergence of extended-spectrum beta-lactamase (ESBL)-producing organisms, complicates empiric treatment strategies. ESBL-producing organisms are clinically relevant because they are frequently associated with multidrug resistance and significantly limit empiric antimicrobial treatment options in urinary tract infections. The study period starting in 2019 was selected to reflect contemporary resistance patterns and to ensure consistency with the updated EUCAST antimicrobial susceptibility interpretation criteria introduced at that time. This study aimed to characterize antimicrobial resistance patterns among uropathogens isolated from lower UTIs and to identify independent predictors of antimicrobial resistance using isolate-level analyses. Methods: This retrospective observational study included 1470 patients and isolates with clinically suspected lower UTIs who underwent urine culture and antimicrobial susceptibility testing between 2019 and 2024 at a single clinical center. Antimicrobial susceptibility was interpreted according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria, and ESBL production was assessed among Gram-negative (GN) isolates. Multivariable generalized estimating equation (GEE) logistic regression models accounting for patient clustering were used to identify predictors of resistance. Results: A total of 1470 patients and isolates were included. Escherichia coli was the most frequent uropathogen (66.0%), followed by Klebsiella pneumoniae and Enterococcus faecalis. Among Gram-negative isolates, 17.3% were ESBL-positive. Resistance rates were highest for ciprofloxacin (35.4%) and trimethoprim/sulfamethoxazole (31.7%), while fosfomycin and nitrofurantoin retained high activity against E. coli. In multivariable analyses, ESBL production was the strongest independent predictor of resistance to several antimicrobials, including ciprofloxacin (aOR 9.83), amoxicillin/clavulanic acid (aOR 3.22), trimethoprim/sulfamethoxazole (aOR 2.89), and cefotaxime (aOR 1337). Pathogen identity was also independently associated with resistance. Conclusions: Antimicrobial resistance among uropathogens was heterogeneous and predominantly driven by pathogen identity and ESBL production. ESBL status emerged as the most consistent and powerful predictor of resistance across multiple antimicrobials, underscoring its clinical relevance for empiric treatment decisions and antimicrobial stewardship in urinary tract infections.

## Linked entities

- **Chemicals:** ciprofloxacin (PubChem CID 2764), trimethoprim/sulfamethoxazole (PubChem CID 358641), fosfomycin (PubChem CID 441029), nitrofurantoin (PubChem CID 6604200), amoxicillin/clavulanic acid (PubChem CID 6435924), cefotaxime (PubChem CID 5742673)
- **Species:** Escherichia coli (taxon 562), Klebsiella pneumoniae (taxon 573), Enterococcus faecalis (taxon 1351)

## Full-text entities

- **Diseases:** bacteriuria (MESH:D001437), pyelonephritis (MESH:D011704), UTI (MESH:D014552), dysuria (MESH:D053159), injury to (MESH:D014947), infection (MESH:D007239), bacterial infections (MESH:D001424)
- **Chemicals:** tigecycline (MESH:D000078304), Linezolid (MESH:D000069349), levofloxacin (MESH:D064704), nitrofurantoin (MESH:D009582), gentamicin (MESH:D005839), clavulanic acid (MESH:D019818), Trimethoprim/sulfamethoxazole (MESH:D015662), cephalosporin (MESH:D002511), Ciprofloxacin (MESH:D002939), ertapenem (MESH:D000077727), Imipenem (MESH:D015378), Aminoglycosides (MESH:D000617), Piperacillin/tazobactam (MESH:D000077725), fluoroquinolones (MESH:D024841), vancomycin (MESH:D014640), ceftriaxone (MESH:D002443), cefotaxime (MESH:D002439), ampicillin (MESH:D000667), beta-lactam (MESH:D047090), Carbapenems (MESH:D015780), Cefuroxime (MESH:D002444), cefepime (MESH:D000077723), ceftazidime (MESH:D002442), amoxicillin/clavulanic acid (MESH:D019980), Fosfomycin (MESH:D005578), MacConkey agar (-), Meropenem (MESH:D000077731), teicoplanin (MESH:D017334), amikacin (MESH:D000583), streptomycin (MESH:D013307), norfloxacin (MESH:D009643), monobactams (MESH:D008997)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Klebsiella pneumoniae (species) [taxon 573], Serratia marcescens (species) [taxon 615], Streptococcus agalactiae (species) [taxon 1311], Enterococcus faecalis (species) [taxon 1351], Pseudomonas aeruginosa (species) [taxon 287], Proteus mirabilis (species) [taxon 584], Homo sapiens (human, species) [taxon 9606], Enterobacterales (order) [taxon 91347]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024478/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024478/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024478/full.md

---
Source: https://tomesphere.com/paper/PMC13024478